ARID1A and cancer: Studies, both preclinical and clinical, have demonstrated that the role of genetics and epigenetics in malignant tumors will be explored further, and mutation of the chromatin remodeling complex subunit, ARID1A, may become a promising tool for individualized treatment targets in patients with GC.